Infliximab Biosimilar Insight, 2022 | DelveInsight

DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Interested to know more about the functioning of Biosimilars, visit @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Geography Covered: Global coverage

Infliximab: Overview

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease.

Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α 1, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α 1

Request for a detailed sample copy of our report @ https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Infliximab Biosimilars: Marketed Drugs
1. Inflectra: Celltrion/Pfizer
2. Renflexis: Merck
Infliximab Biosimilars: Emerging Drugs
1. BCD 055: Biocad
2. CT-P17: Celltrion
Major Players in Infliximab

There are approximately 20+ Infliximab biosimilars key companies which are developing the therapies for Infliximab.

To understand key companies related to the Infliximab Biosimilars Market, get a snapshot @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Infliximab Biosimilars Report Highlights:
1. The companies and academics are working to assess challenges and seek opportunities that could influence Infliximab R&D. The therapies under development are focused on novel approaches to treat/improve Infliximab.
2. In July 2017, Merck had launched in the U.S. a biosimilar of Remicade (infliximab), the blockbuster immune-mediated inflammatory disorders treatment it markets outside the U.S., including Europe, while partner Janssen Biotech markets the drug stateside.
3. In December 2017, Pfizer announced that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade (infliximab) for all eligible indications of the reference product. The FDA has approved IXIFI as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

For detailed Infliximab Biosimilars Report Highlights, visit here @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents:

1. Key Insights
2. Infliximab Biosimilars: Snapshot
3. Executive Summary
4. Regulatory Outlook For Biosimilars
5. Infliximab (Reference Product: Remicade)
6. Research and Development
7. Remicade Biosimilar: Emerging Opportunities
8. Infliximab: Biosimilars Assessment
9. Infliximab Biosimilars Profiles: By Company
10. Infliximab Biosimilars: Comparative Landscape: By Company
11. Infliximab Biosimilars: Competitive Landscape
12. Market Drivers
13. Market Barriers
14. SWOT Analysis
15. Appendix
16. Bibliography
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

Reqest for a detailed TOC of the Infliximab Biosimilars Report @ https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.